Biolidics partners Japan's Sysmex Corp for cancer-related R&D

Biolidics partners Japan's Sysmex Corp for cancer-related R&D

Michelle Zhu
20/02/19, 06:19 pm

SINGAPORE (Feb 20): Biolidics Limited has established a strategic partnership with Sysmex Corporation, a Tokyo Stock Exchange-listed supplier of hematology instruments, to collaborate on the development of laboratory assays in the field of circulating tumour cells.

See: Biolidics selling 27.5 mil new shares at 28 cents each in conjunction with Catalist listing

The endeavor will use Biolidic’s ClearCell FX1 System and Sysmex’s molecular imaging flow cytometer MI-FCM in Japan and Singapore, respectively.

Under the non-binding term sheet signed by both parties today, Biolidics and Sysmex intend to laboratory assay developments, applications and market developments for the potential commercialisation of these laboratory assays.

In a Wednesday filing, Biolidics says its ClearCell FX1 System has the potential to serve as a platform technology for the diagnosis, prognosis, treatment selection and treatment monitoring of various types of cancers, through the development of a wide range of clinical or laboratory assays.

With Sysmex as a strategic partner, the group believes this will enhance the commercial scalability of its technology and allowing the ClearCell FX1 System to be used in a greater number of hospitals and laboratories globally – in line with its key business focus of developing end-to-end diagnostic solutions which integrate its cell separation and enrichment technology with other analytical tests.

“By forging this strategic collaboration, Biolidics will be ideally positioned to increase the sales potential of our ClearCell FX1 System and CTChip FR1 biochip once these blood-based assays are approved clinically,” says Ivan Lew, executive director and CEO of Biolidics.

Shares in the group closed flat at 30 cents on Wednesday.

Right timing: STI’s upclimb supported by momentum and moving averages

SINGAPORE (Apr 20): There has been little change in the trend and chart pattern of the Straits Times Index. The index has been on a very glacial ascent towards 3,420, the target indicated when the index broke out of resistance at 3,190 in mid-Jan. Quarterly momentum eased during the past four trading sessions. The 100- and 200-day moving averages have turned positive. This coupled with positively placed DIs and rising ADX should continue to underpin the STI. The only cautionary signals are the somewhat overbought levels of short term stochastics and 21-day RSI, and stagnant vol....

SMI takes legal action against Hyflux; Maybank moves on Tuaspring

(Apr 20): SM Investments (SMI) has terminated its rescue agreement with Hyflux, it announced on Friday. Hyflux, on its part, had already on April 4 terminated the same agreement with SMI. SMI claims it has thus far abided by the agreement. “To clarify, SMI does not accept the purported termination of the Restructuring Agreement by Hyflux on 4 April 2019. This is because the termination was not in accordance with the terms of the Restructuring Agreement," said SMI. Under the agreement reached last October, SMI, led by Indonesian tycoon Anthoni Salim, was to have invested $530 million in....

CCT reports 3.8% higher 1Q DPU of 2.20 cents on higher property contributions

SINGAPORE (April 19): The manager of CapitaLand Commercial Trust (CCT) has reported a 1Q19 distribution per unit (DPU) of 2.20 cents, rising 3.8% y-o-y from 2.12 cents due to higher contributions from Gallileo and Asia Square Tower 2. Gross revenue and net property income (NPI) for the quarter increased by 3.5% and 3.4% to $99.8 million and $79.8 million, respectively. This comes after booking contributions from Gallileo – an office building in Frankfurt, Germany which the trust acquired a 94.9% stake in during June 2018 – as well as higher occupancy at Asia Square Tower 2, both of w....